SCHEMBL5865240

SCHEMBL5865240

COc1ccc(C(CC(=O)NCc2ccc(NC(=O)Nc3ccccc3C)cc2)NC(=O)c2ccc(C(=O)O)cc2)cc1OC

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ITGB1 P05556 8/20 0.58
ITGA4 P13612 8/20 0.58
SMN1; SMN2 Q16637 2/20 0.47
NR1H4 Q96RI1 1/20 0.46
ITGB7 P26010 1/20 0.46
NAMPT P43490 3/20 0.45
TNF P01375 1/20 0.44
HDAC1 Q13547 2/20 0.43
HDAC2 Q92769 2/20 0.43
MAPT P10636 3/20 0.43
LMNA P02545 2/20 0.43
MEN1 O00255 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
KMT2A Q03164 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5896625 0.92 ITGB1 (0.58) ITGB1ITGA4SMN1; SMN2ITGB7MAPT
SCHEMBL5897283 0.90 ITGB1 (0.53) ITGB1ITGA4ITGB7NAMPTHDAC1
SCHEMBL5897280 0.90 ITGB1 (0.53) ITGB1ITGA4SMN1; SMN2NR1H4ITGB7
SCHEMBL6353998 0.84 ITGB1 (0.61) ITGB1ITGA4SMN1; SMN2ITGB7TNF
SCHEMBL6344233 0.82 ITGB1 (0.59) ITGB1ITGA4SMN1; SMN2ITGB7
SCHEMBL5896459 0.82 ITGB1 (0.53) ITGB1ITGA4SMN1; SMN2ITGB7MAPT
SCHEMBL5896454 0.81 ITGB1 (0.53) ITGB1ITGA4SMN1; SMN2ITGB7MAPT
SCHEMBL5896446 0.81 MAPT (0.61) ITGB1ITGA4SMN1; SMN2ITGB7MAPT
SCHEMBL5700895 0.80 ITGA4 (0.72) ITGB1ITGA4ITGB7MEN1KMT2A
SCHEMBL5700892 0.80 ITGA4 (0.72) ITGB1ITGA4ITGB7MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7091242-B2 Beta-amino acid derivatives as integrin receptor antagonists BAYER AKTIENGESELLSCHAFT (DE) 2006-08-15 US disclosed
US-7064229-B2 ethyl 4-[(4-[[2-methyl-phenyl)amino]carbonyl]amino)phenyl]amino]-4-oxo-2-phenyl-butanoyl)amino]benzoate for treatment of inflammatory diseases and conditions mediated by integrins (atherosclerosis, asthma, obstructive pulmonary disease, allergies, diabetes, multiple sclerosis, and autoimmune disorders) BAYER HEALTHCARE AG (DE) 2006-06-20 US disclosed
US-20040058904-A1 Beta-amino acid derivatives as integrin receptor antagonists BAYER AKTIENGESELLSCHAFT (DE) 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058904-A1 Beta-amino acid derivatives as integrin receptor antagonists ITGAL, ITGB1, ITGB2 ITGB1 2/4885ITGA4 15/4885SMN1; SMN2 3289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.